Autoantibody-associated cross-reactive idiotypes expressed at high frequency in chronic lymphocytic leukemia relative to B-cell lymphomas of follicular center cell origin.
Using murine monoclonal antibodies (MoAbs) specific for immunoglobulin (Ig) cross-reactive idiotypes (CRI), we performed immunohistochemical analyses on frozen tissue sections and cytocentrifuge preparations of Ig-expressing malignant cells from patients with chronic lymphocytic leukemia (CLL) and B-cell non-Hodgkin's lymphomas (NHL) of follicular center cell origin. Twenty percent (4/20) of the Ig kappa light chain-expressing CLL cells reacted with 17.109, a MoAb against a major CRI on human IgM autoantibodies that is encoded by a conserved Ig variable-region gene (V gene) of the V kappa IIIb sub-subgroup. Another MoAb specific for V kappa IIIb framework determinant(s) reacted exclusively with all the 17.109-reactive CLL cells. Only one of 20 kappa light-chain-expressing CLL cells reacted with 6B6.6, a monoclonal antibody specific for a CRI commonly found on rheumatoid factor (RF) paraproteins with light-chain variable regions of the V kappa IIIa sub-subgroup. Finally, greater than 20% (8/34) of all CLL reacted with G6, a MoAb specific for an Ig heavy chain-associated CRI present on several RF paraproteins. In contrast, these CRIs were expressed at significantly lower frequencies in NHL of follicular center cell origin. Only one of 30 NHL expressing kappa light chains reacted with the 17.109 MoAb. Also, in contrast to the concordance between the 17.109-CRI and V kappa IIIb framework determinant(s) in CLL, two lymphomas in addition to the 17.109-reactive lymphoma were recognized by the anti-V kappa IIIb framework MoAb. None of the NHL reacted with either the 6B6.6 or the G6 MoAbs. These results are the first to demonstrate that CLL and NHL differ with respect to the expression of autoantibody-associated CRIs. The data support the notion that NHL of follicular center cell origin differs from CLL in its utilization and/or somatic mutation of Ig variable-region genes. The physiological and immunotherapeutic implications of these findings are discussed.
Kipps
T J
TJ
Department of Basic and Clinical Research, Research Institute of Scripps Clinic, La Jolla 92037.
Robbins
B A
BA
Kuster
P
P
Carson
D A
DA
D001323:Autoantibodies / Q000276:immunology*; D001402:B-Lymphocytes; D003429:Cross Reactions; D006801:Humans; D007130:Immunoglobulin Idiotypes / Q000032:analysis*; D007135:Immunoglobulin Variable Region / Q000235:genetics; D007167:Immunotherapy; D007945:Leukemia, Lymphoid / Q000276:immunology* / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000276:immunology*; D009154:Mutation; D011947:Receptors, Antigen, B-Cell / Q000032:analysis
D001323:Autoantibodies; D007130:Immunoglobulin Idiotypes; D007135:Immunoglobulin Variable Region; D011947:Receptors, Antigen, B-Cell